(0.31%) 5 115.70 points
(0.30%) 38 355 points
(0.35%) 15 983 points
(-0.98%) $83.03
(5.36%) $2.03
(0.29%) $2 354.00
(0.36%) $27.64
(4.12%) $960.05
(-0.26%) $0.932
(-0.47%) $10.97
(-0.57%) $0.796
(1.66%) $93.40
@ $3.74
発行日: 15 2月 2024 @ 02:33
リターン: -25.67%
前回のシグナル: 2月 15 - 01:06
前回のシグナル:
リターン: 0.00 %
Live Chart Being Loaded With Signals
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally...
Stats | |
---|---|
本日の出来高 | 231 659 |
平均出来高 | 1.29M |
時価総額 | 389.36M |
EPS | $0 ( 2024-03-26 ) |
次の収益日 | ( $0 ) 2024-05-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -13.90 |
ATR14 | $0.00500 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-08 | Ekblom Anders | Buy | 45 000 | Share Options (Right to buy) |
2024-02-08 | Ekblom Anders | Buy | 19 471 | Deferred Restricted Stock Units |
2024-02-08 | Jacquet Pierre | Buy | 45 000 | Share Options (Right to buy) |
2024-02-08 | Jacquet Pierre | Buy | 15 553 | Deferred Restricted Stock Units |
2024-02-08 | Yoskowitz Marc J | Buy | 45 000 | Share Options (Right to buy) |
INSIDER POWER |
---|
-60.64 |
Last 97 transactions |
Buy: 2 158 393 | Sell: 9 188 547 |
ボリューム 相関
Mereo BioPharma Group plc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Mereo BioPharma Group plc 相関 - 通貨/商品
Mereo BioPharma Group plc 財務諸表
Annual | 2023 |
収益: | $10.00M |
総利益: | $7.43M (74.26 %) |
EPS: | $0 |
FY | 2023 |
収益: | $10.00M |
総利益: | $7.43M (74.26 %) |
EPS: | $0 |
FY | 2022 |
収益: | $1.51M |
総利益: | $571 000 (37.89 %) |
EPS: | $-0.280 |
FY | 2021 |
収益: | $36.46M |
総利益: | $18.56M (50.89 %) |
EPS: | $0.159 |
Financial Reports:
No articles found.
Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。